Skip to content

Clinical Trials of CT-guided Percutaneous Irreversible Electroporation(IRE)in the Treatment of Patients With Locally Advanced Tumors

Clinical Trials of CT-guided Percutaneous Irreversible Electroporation(IRE)in the Treatment of Patients With Locally Advanced Tumors:The Safety and Efficacy Assessment

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02567734
Enrollment
20
Registered
2015-10-05
Start date
2015-10-31
Completion date
2017-01-31
Last updated
2015-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Neoplasms

Keywords

irreversible electroporation, ablation, neoplasms, cancer, carcinoma, NanoKnife, Ablation Techniques

Brief summary

Irreversible electroporation (IRE) is an emerging nonthermal focal ablation technique that uses a series of short but intense electric pulses delivered by NanoKnife generator through paired electrodes into a targeted region of tissue, inducing the cells death by apoptosis through irreversibly disrupting cellular membrane integrity. This study aimed to investigate the safety and efficacy of CT-guided percutaneous irreversible electroporation(IRE) in the treatment of patients with locally advanced tumors in different anatomical position.

Detailed description

This study is a multicenter, open-label trial that aimed to evaluate the safety and efficacy of CT-guided percutaneous irreversible electroporation(IRE)in the treatment of patients with locally advanced tumors. Investigators will screen eligible patients and examine them by imaging tests as well as serological examination before and after the IRE procedures to assess the result with the size,blood supply,metabolism of tumors,the change of blood test and treatment-related complications. Big bore multislice spiral CT with thickness 5 cm, 120kilovolt,and 250milliampere,ECG-gated device and anesthesia monitoring equipment were selected during these procedures. Imaging (performed by contrast enhanced CT scan) and serological follow-up was at postoperative day 3 and 1,3,6,12months. The primary endpoint is the effective rate of IRE,and the secondary endpoint is 1-year survival rate and the frequency of adverse events. The response of irreversible electroporation ablation will be assessed according to the different evaluation criterions based on Response Evaluation Criteria in Solid Tumors.

Interventions

PROCEDURECT-guided percutaneous irreversible electroporation

Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.

Sponsors

Yueyong Xiao
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Histologically confirmed locally advanced solid tumor. 2. Unresectable tumors or the patient refused surgical therapy. 3. Patients in good health conditions can receive general anesthesia. 4. Patients with good compliance can cooperate with doctors for related tests and the regular follow-up.

Exclusion criteria

1. Targeted tissues that metallic wallstents or metallics were implanted. 2. With heart pacemaker or be allergic to contrast medium that can not have related imaging examinations. 3. With bleeding and psychiatric disorders. 4. Severe arrhythmia.

Design outcomes

Primary

MeasureTime frameDescription
effective rate of IRE ablationup to 12 months after the proceduresThe procedure-related result will be assess by the size,blood supply,metabolism of the tumors. The changes of blood test are also considerable.

Secondary

MeasureTime frameDescription
1-year survival ratesup to 12 months after the procedures
complication rateDuring the procedure or up to 12 months after the ablation procedurethe frequency of adverse events,including early and late complications

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026